TIDES Europe: Oligonucleotide and Peptide Therapeutics is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Gilles Divita
CEO at Divincell SAS

Profile

Dr. Gilles Divita is founder and CEO of DIVINCELL, a BioPharmaceutical NanoMedicine Start-up pioneering a novel drug delivery technology for the treatment of cancer and genetic diseases. Dr Divita has over 25 years of experience in drug delivery systems, peptide-drugs and oligonucleotide therapeutics. He is one of the pioneers of the “non covalent cell penetrating peptide-based strategy” for therapeutic delivery.

Dr. Divita holds a Ph.D. in Biochemistry/Biophysic from the University in Lyon, France. He worked as Post Doc at the Max Planck Institute in Heidelberg-Germany and as Associate Professor at the SCRIPPS Research Institute, La jolla, USA. In 1996, Dr. Divita joined the French National Center for Scientific Research (CNRS) and was Research Director, head of Chemical Biology and Nanotechnology for Therapeutics Team at the CNRS in Montpellier-France up to 2016.

Gilles Divita's Network

Agenda Sessions

  • Nanocarrier for CRISPR Gene Editing and mRNA-mediated Tumor Suppressor Rescue

    , 15:15

Speakers at this event